Considering the high frequency of MAPK pathway abnormalities, particularly in MPNST, MEK inhibitor treatment may prove effective based on preclinical data, warranting further evaluation through clinical trials (193). Here, MAP2K7 is linked to malignant peripheral nerve sheath tumor.